A Randomized, Double-blind, Phase I Study Comparing the Pharmacokinetic and Safety of SIBP-04 and Bevacizumab in Healthy Male Subjects
Latest Information Update: 01 Jan 2024
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Shanghai Institute of Biological Products
Most Recent Events
- 24 Dec 2023 Status changed from not yet recruiting to completed.
- 01 Nov 2019 New trial record